From: No association of TNFRSF1B variants with type 2 diabetes in Indians of Indo-European origin
Initial phase | Replication phase | |||
---|---|---|---|---|
Characteristics | Type 2 diabetes patients | Control Subjects | Type 2 diabetes patients | Control subjects |
N (Men/Women) | 1019 (592/427) | 1006 (606/400) | 1047 (619/428) | 1038 (516/522) |
Age (years) | 53 (45-62) | 50 (44-60) | 55 (49-62) | 54 (45-64) |
BMI (Kg/m2) | ||||
Men | 23.8 (22.0-26.0) | 23.1 (20.1-25.7) | 24.8 (22.7-27.8) | 24.7 (22.3-27.4) |
Women | 26.7 (24.2-29.2) | 25.0 (21.1-28.5) | 27.4 (24.6-30.6) | 26.4 (23.1-29.3) |
WHR | ||||
Men | 1.00 (0.97-1.03) | 0.97 (0.92-1.0) | 0.98 (0.95-1.03) | 0.97 (0.93-1.01) |
Women | 1.00 (0.97-1.03) | 0.86 (0.82-0.92) | 0.93 (0.87-0.97) | 0.86 (0.82-0.90) |
Systolic BP (mmHg) | 130 (130-140) | 120 (112-132) | 130 (122-140) | 130 (120-140) |
Diastolic BP (mmHg) | 80 (78-90) | 80 (70-88) | 82 (80-90) | 80 (78-90) |
HbA1c (%) | 7.8 (6.5-9.4) | 5.2 (4.9-5.6) | 8.2 (6.9-9.6) | 5.6 (5.3-5.9) |
FPG (mmol/L) | 7.9 (6.4-10.3) | 4.9 (4.5-5.3) | 7.8 (6.2-10.3) | 4.9 (4.4-5.3) |
FPI (pmol/L) | 82.8 (42.0-166.8) | 32.4 (17.4-57.6) | 74.4 (26.0-96.0) | 43.8 (28.2-63.6) |
HOMA-IR | 5.20 (2.30-9.60) | 1.20 (0.60-2.00) | 4.30 (2.30-9.30) | 1.60 (1.00-2.40) |
C-peptide (nmol/L) | 0.89 (0.56-1.36) | 0.53 (0.36-0.73) | 1.05 (0.69-1.60) | 0.66 (0.50-0.86) |
hsCRP (mg/L) | 2.20 (0.90-4.70) | 1.30 (0.60-3.00) | 1.86 (0.90-3.44) | 1.61 (0.90-3.04) |
TC (mmol/L) | 4.20 (3.50-5.00) | 4.40 (3.7-5.10) | 4.64 (3.86-5.42) | 4.91 (4.22-5.52) |
LDL-C (mmol/L) | 2.57 (1.99-3.36) | 2.79 (2.33-3.41) | 2.73 (2.10-3.42) | 3.01 (2.49-3.51) |
HDL-C (mmol/L) | 1.03 (0.88-1.22) | 1.06 (0.88-1.28) | 1.11 (0.94-1.34) | 1.24 (1.06-1.46) |
TG (mmol/L) | 1.60 (1.10-2.20) | 1.30 (1.00-1.80) | 1.43 (0.98-2.13) | 1.22 (0.86-1.64) |